1. A real-world risk analysis of biological treatment (adalimumab and etanercept) in a country with a high prevalence of tuberculosis and chronic liver disease: a nationwide population-based study. (4th May 2017) Authors: Chiu, Y-M; Tang, C-H; Hung, S-T; Yang, Y-W; Fang, C-H; Lin, H-Y Journal: Scandinavian journal of rheumatology Issue: Volume 46:Number 3(2017) Page Start: 236 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗